133 related articles for article (PubMed ID: 37663012)
1. Patient Preference for Once-Weekly Dosing in Type 2 Diabetes Mellitus in Japan.
Sen R; Shields AL; Atsuda K
J Health Econ Outcomes Res; 2016; 4(1):55-66. PubMed ID: 37663012
[No Abstract] [Full Text] [Related]
2. A survey of patient preferences for oral antihyperglycemic therapy in patients with type 2 diabetes mellitus.
Hauber AB; Tunceli K; Yang JC; Gantz I; Brodovicz KG; Alexander CM; Davies MJ; Radican L
Diabetes Ther; 2015 Mar; 6(1):75-84. PubMed ID: 25586555
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naïve Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study.
Qin L; Chen S; Flood E; Shaunik A; Romero B; de la Cruz M; Alvarez C; Grandy S
Diabetes Ther; 2017 Apr; 8(2):321-334. PubMed ID: 28155131
[TBL] [Abstract][Full Text] [Related]
4. Patients' preferences for once-daily oral versus once-weekly injectable diabetes medications: The REVISE study.
Boye K; Ross M; Mody R; Konig M; Gelhorn H
Diabetes Obes Metab; 2021 Feb; 23(2):508-519. PubMed ID: 33140575
[TBL] [Abstract][Full Text] [Related]
5. Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation.
Yu M; Xie J; Fernandez Lando L; Kabul S; Swindle RW
Clin Ther; 2016 Jan; 38(1):149-60. PubMed ID: 26706658
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom.
Qin L; Chen S; Flood E; Shaunik A; Romero B; de la Cruz M; Alvarez C; Grandy S
Diabetes Ther; 2017 Apr; 8(2):335-353. PubMed ID: 28236271
[TBL] [Abstract][Full Text] [Related]
7. Systematic Literature Review and Meta-analysis of Medication Adherence With Once-weekly Versus Once-daily Therapy.
Iglay K; Cao X; Mavros P; Joshi K; Yu S; Tunceli K
Clin Ther; 2015 Aug; 37(8):1813-21.e1. PubMed ID: 26117406
[TBL] [Abstract][Full Text] [Related]
8. Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.
Meloni AR; DeYoung MB; Han J; Best JH; Grimm M
Cardiovasc Diabetol; 2013 Mar; 12():48. PubMed ID: 23522121
[TBL] [Abstract][Full Text] [Related]
9. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
Weng J
J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.
Nguyen H; Dufour R; Caldwell-Tarr A
Adv Ther; 2017 Mar; 34(3):658-673. PubMed ID: 28078541
[TBL] [Abstract][Full Text] [Related]
11. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States.
Johnston SS; Nguyen H; Felber E; Cappell K; Nelson JK; Chu BC; Kalsekar I
Adv Ther; 2014 Nov; 31(11):1119-33. PubMed ID: 25408484
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study.
Inagaki N; Atsumi Y; Oura T; Saito H; Imaoka T
Clin Ther; 2012 Sep; 34(9):1892-908.e1. PubMed ID: 22884767
[TBL] [Abstract][Full Text] [Related]
13. Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily.
Best JH; Boye KS; Rubin RR; Cao D; Kim TH; Peyrot M
Diabet Med; 2009 Jul; 26(7):722-8. PubMed ID: 19573122
[TBL] [Abstract][Full Text] [Related]
14. Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.
Johnston SS; Nguyen H; Cappell K; Nelson JK; Chu BC; Kalsekar I
J Med Econ; 2015; 18(9):666-77. PubMed ID: 25867133
[TBL] [Abstract][Full Text] [Related]
15. [Adherence to Oral Antihyperglycemic Agents (Dipeptidyl Peptidase-4 Inhibitors and Biguanides) and Its Associated Factors in Patients with Type 2 Diabetes].
Hayashi A; Kubo T; Okuyama K; Tokita S; Kamei M
Yakugaku Zasshi; 2019; 139(12):1569-1581. PubMed ID: 31787647
[TBL] [Abstract][Full Text] [Related]
16. A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes.
Hauber AB; Nguyen H; Posner J; Kalsekar I; Ruggles J
Curr Med Res Opin; 2016; 32(2):251-62. PubMed ID: 26549576
[TBL] [Abstract][Full Text] [Related]
17. Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis.
Zimner Rapuch S; Divino V; Norrbacka K; Boye K; Lebrec J; Rosilio M; DeKoven M; Guerci B
Diabetes Ther; 2021 May; 12(5):1553-1567. PubMed ID: 33864629
[TBL] [Abstract][Full Text] [Related]
18. Exenatide Once Weekly for Management of Type 2 Diabetes: A Review.
Inaishi J; Saisho Y
Clin Pharmacol; 2022; 14():19-26. PubMed ID: 35422660
[TBL] [Abstract][Full Text] [Related]
19. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
Cramer JA; Amonkar MM; Hebborn A; Altman R
Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of exenatide twice daily and exenatide once weekly in Asian versus White patients with type 2 diabetes mellitus: A pooled analysis.
Sheu WH; Brunell SC; Blase E
Diabetes Res Clin Pract; 2016 Apr; 114():160-72. PubMed ID: 26827116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
